$PFE Recent Headlines AstraZeneca lifts 2014 guidance

New Post Public Reply Private Reply Replies (0) Message Board

Nov 9, 2014 at 12:23 PM

$PFE Recent Headlines

AstraZeneca lifts 2014 guidance as profit slides 2:33 a.m. Nov. 6, 2014 - MarketWatch.com
Facebook, Gilead shares fall after hours 6:14 p.m. Oct. 28, 2014 - Sue Chang
Updates, advisories and surprises 5:01 p.m. Oct. 28, 2014 - MarketWatch
5 ways to profit from sex (without having it) 1:24 p.m. Oct. 28, 2014 - Charles Passy
‘Dumb money’ unloads bullish oil bets as prices pose threat to stocks 8:35 a.m. Oct. 28, 2014 - Shawn Langlois
Newscast: Feds kick off two-day meeting 7:37 a.m. Oct. 28, 2014 - MarketWatch
Pfizer sales fall less than expected 7:34 a.m. Oct. 28, 2014 - MarketWatch.com
Pfizer's stock rallies after earnings, sales beat expectations 7:16 a.m. Oct. 28, 2014 - Tomi Kilgore
Pfizer's stock rises 1.8% premarket after Q3 results 7:04 a.m. Oct. 28, 2014 - Tomi Kilgore
Pfizer revises 2014 sales outlook to $48.7 bln-$49.7 bln from $48.7 bln-$50.7 bln 7:03 a.m. Oct. 28, 2014 - Tomi Kilgore
Pfizer revises 2014 EPS outlook to $2.23-$2.27 from $2.20-$2.30 7:02 a.m. Oct. 28, 2014 - Tomi Kilgore
Pfizer Q3 sales tops FactSet consensus $12.28 bln 7:02 a.m. Oct. 28, 2014 - Tomi Kilgore
Pfizer Q3 sales $12.36 bln vs. $12.64 bln a year ago 7:01 a.m. Oct. 28, 2014 - Tomi Kilgore
Pfizer Q3 net EPS 42 cents vs. 39 cents a year ago 7:01 a.m. Oct. 28, 2014 - Tomi Kilgore
Pfizer Q3 adj. EPS 57 cents vs. FactSet consensus 55 cents 7:01 a.m. Oct. 28, 2014 - Tomi Kilgore
What to look for in Pfizer earnings 4:44 p.m. Oct. 27, 2014 - Jonathan D. Rockoff
‘Monsters under the bed’ threaten market’s seasonal boost 9:09 a.m. Oct. 27, 2014 - Shawn Langlois
Pfizer ends agreement to develop Remoxy 9:05 a.m. Oct. 27, 2014 - Tess Stynes
Pain Therapeutics, Durect shares tumble after Pfizer discontinues development pact 8:46 a.m. Oct. 27, 2014 - Tomi Kilgore
Energy, health care earnings to dominate week 5:02 a.m. Oct. 26, 2014 - Wallace Witkowski

Money for Nothing 4:36 a.m. Nov. 8, 2014 - Barrons.com
MannKind Is On The Mend 7:07 p.m. Nov. 7, 2014 - Seeking Alpha
Tracking Kahn Brothers Portfolio - Q3 2014 Update 2:17 a.m. Nov. 7, 2014 - Seeking Alpha
Will Pfizer Sweeten Its Bid For AstraZeneca? 5:41 p.m. Nov. 6, 2014 - Investors Business Daily
10-Q: PFIZER INC 5:07 p.m. Nov. 6, 2014 - Edgar Online - (EDG = 10Q, 10K)
Move Over Federal Reserve, There's a New Central Bank in Town 2:35 p.m. Nov. 6, 2014 - TheStreet.com
CEO-Less Sanofi Tries to Regain Mojo 1:50 p.m. Nov. 6, 2014 - The Wall Street Journal Interactive Edition
AstraZeneca Needs to Account for Next Year’s Challenges 10:34 a.m. Nov. 6, 2014 - The Wall Street Journal Interactive Edition
Divided Government Won't Halt Wall Street's Run 9:58 a.m. Nov. 6, 2014 - FOXBusiness
AstraZeneca Profit Outlook Improves 7:39 a.m. Nov. 6, 2014 - The Wall Street Journal Interactive Edition
Biosimilars: The Good, the Bad and the Unknown 7:27 a.m. Nov. 6, 2014 - Barrons.com
Monotype Gets Its Font Tech Deeper Into Advertising 5:26 p.m. Nov. 5, 2014 - Investors Business Daily
Warburg Pincus-Owned GT Nexus Explores Sale 2:28 p.m. Nov. 4, 2014 - The Wall Street Journal Interactive Edition
VRX, CELG And PFE, Pushing Drugs Industry Downward 2:13 p.m. Nov. 4, 2014 - TheStreet.com
Zoetis Q3 Earnings Beat Driven by Higher Livestock Sales - Analyst Blog 12:50 p.m. Nov. 4, 2014 - Zacks.com
"Goodbye Mr. Jones": The End Of The Dow As An American Index 10:12 a.m. Nov. 4, 2014 - Seeking Alpha
Zoetis Rides Livestock as Results Top Expectations 9:17 a.m. Nov. 4, 2014 - The Wall Street Journal Interactive Edition
AstraZeneca Is Attractive Even Without Pfizer Bid 8:19 a.m. Nov. 4, 2014 - Seeking Alpha
Minerals Technologies Digs Up A Winner With Buyout 12:47 p.m. Nov. 3, 2014 - Investors Business Daily
7 Old Dividend Dogs Of Healthcare Aim At 11% To 30.5% October Upsides 12:21 p.m. Nov. 3, 2014 - Seeking Alpha

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference 11:00 a.m. Nov. 5, 2014 - BusinessWire - BZX
Pharma Stocks on our Radar - Pfizer, Merck, Sanofi, Shire, and Zogenix 8:55 a.m. Nov. 4, 2014 - PR Newswire - PRF
Pfizer Receives FDA Accelerated Approval for TRUMENBA® (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Adolescents and Young Adults 2:44 p.m. Oct. 29, 2014 - BusinessWire - BZX
Compliance Notice, Dividend Announcements, New Share Repurchase Program, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Edwards and Lilly 8:35 a.m. Oct. 29, 2014 - PR Newswire - PRF
Pfizer’s PRISTIQ® (desvenlafaxine) Demonstrates Low Potential For Sexual Dysfunction in Adults with Major Depressive Disorder 8:30 a.m. Oct. 29, 2014 - BusinessWire - BZX
Time Magazine Warns Against Investing In Certain "Ebola Stocks" 9:22 a.m. Oct. 28, 2014 - ACCESSWIRE
DURECT Provides Update on REMOXY® and POSIDUR™ Programs 8:05 a.m. Oct. 27, 2014 - PR Newswire - PRF
Pfizer to Discontinue Agreement on REMOXY™ (oxycodone) Extended-Release Capsules CII 8:02 a.m. Oct. 27, 2014 - BusinessWire - BZX
Pain Therapeutics to Regain Full Rights to REMOXY(R) 8:01 a.m. Oct. 27, 2014 - GlobeNewswire
Pfizer Declares 26-Cent Fourth-Quarter 2014 Dividend 4:08 p.m. Oct. 23, 2014 - BusinessWire - BZX
Pfizer Wins SUTENT® Patent Case In Delaware District Court 8:05 a.m. Oct. 23, 2014 - BusinessWire - BZX
ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern U.S. 9:00 a.m. Oct. 20, 2014 - PR Newswire - PRF
Acquisition Updates, Drug Approval, Drug Development Discontinuation, and Contract Update - Research Reports on AbbVie, Gilead, Pfizer, Lilly and Aetna 8:35 a.m. Oct. 20, 2014 - PR Newswire - PRF
Pfizer Announces FDA Acceptance Of Palbociclib New Drug Application With Priority Review 11:59 a.m. Oct. 13, 2014 - BusinessWire - BZX
Marketing Application Update, Acquisitions, Collaborations, FDA Approvals, and Structural Changes - Research Reports on Gilead, BD, Pfizer, AbbVie and Novartis 8:55 a.m. Oct. 10, 2014 - PR Newswire - PRF
Pfizer to Present New Data Evaluating Safety, Tolerability and Immunogenicity of its Investigational Staphylococcus aureus Vaccine Candidate at IDWeek 2014™ 8:00 a.m. Oct. 10, 2014 - BusinessWire - BZX
Top 10 Health Care Trends Report Finds Opportunities to Achieve "Triple Aim" 2:45 p.m. Oct. 9, 2014 - PR Newswire - PRF
Kane Biotech Appoints Mark Nawacki to the Board of Directors 8:06 a.m. Oct. 8, 2014 - Marketwired
Pfizer To Present Safety And Immunogenicity Data From A Phase 2 Study Of Its Investigational Meningococcal Group B Vaccine, Bivalent rLP2086, Co-Administered With A Licensed Human Papillomavirus Vaccine 8:01 a.m. Oct. 8, 2014 - BusinessWire - BZX
Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study of Andexanet Alfa and Eliquis (Apixaban) Met Primary and Secondary Endpoints With High Statistical Significance 8:00 a.m. Oct. 1, 2014 - GlobeNewswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RYBREVANT's Promising Results in HNSCC Treatment

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Redwood and SAP Partner on Secure File Transfer

Redwood Advances SAP Interiors with New File Solution October 26, '26 is now a landmark for Redwood Software. They've just rolled out their SAP Managed File Transfer solution. Got the brainpower behind Redwood and SAP operating together here, and they're offering this to enterprises aimed at optimizing their file-based workflow. If you're scratching your head just hearing...

Vantrue's Black Friday Dash Cam Deals: Save up to 44%

Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...

Community in Shock After Fatal Bakersfield Shooting

The Ripple Effect of Tragedy Grief has a way of shaking a community down to its core—especially when the loss emanates from such senseless violence as the shooting death of 17-year-old Levi Brown. This wasn't just a tragic occurrence at a Friday night football game in Bakersfield; it was a visceral crack in the perceived safety of community events. Levi's Legacy and...

DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

BAIC FOTON Eyes African Market with Strategic Moves

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

CapCut's Role in AI-Assisted Small Biz Marketing

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Tennessee's Bold Lung Cancer Trial Signals Innovation

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...

Clarins Dazzles Austin with Skin Longevity Event

Clarins Takes Austin by Storm Under the vast Austin sky, something remarkable unfolded as Clarins transformed the scene with a flashy rooftop affair that screamed innovation and elegance. They weren’t just showing off fancy bottles of beauty potion; they were stirring the pot, merging science with a splash of high-end glitz. This wasn’t just another product pitch—it...

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...